Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

Int J Antimicrob Agents. 2021 Jul;58(1):106353. doi: 10.1016/j.ijantimicag.2021.106353. Epub 2021 May 5.

Abstract

Multicenter surveillance of antimicrobial susceptibility was performed for 235 vancomycin-resistant Enterococcus faecium (VREfm) isolates from 18 Taiwanese hospitals. The minimum inhibitory concentrations (MICs) of eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics were determined using the broth microdilution method. Nearly all isolates of VREfm were not susceptible to teicoplanin, dalbavancin, and telavancin, with susceptibility rates of 0.5%, 1.7% and 0.5%, respectively. Tigecycline and eravacycline were active against 93.2% and 89.7% of the VREfm isolates, respectively. Moreover, the susceptibility rates of quinupristin/dalfopristin, tedizolid, and linezolid were 59.1%, 84.2%, and 77.4%, respectively. Additionally, 94% of the VREfm isolates were classified as susceptible to daptomycin, and the MICs of omadacycline required to inhibit VREfm growth by 50% and 90% were 0.12 and 0.5 mg/L, respectively. Susceptibility rates of VREfm isolates to synthetic tetracyclines and daptomycin were slightly lower and to oxazolidinone-class antibiotics were much lower in Taiwan than those in other parts of the world. Continuous monitoring of VREfm resistance to novel antibiotics, including synthetic tetracyclines, oxazolidinone-class antibiotics, and daptomycin, is needed in Taiwan.

Keywords: Eravacycline; Lipoglycopeptides; Omadacycline; Tedizolid; Vancomycin-resistant Enterococcus faecium.

Publication types

  • Multicenter Study

MeSH terms

  • Aminoglycosides / pharmacology
  • Anti-Bacterial Agents / pharmacology*
  • Bacteremia / microbiology
  • Daptomycin / pharmacology
  • Drug Resistance, Bacterial
  • Enterococcus faecium / drug effects*
  • Enterococcus faecium / isolation & purification
  • Epidemiological Monitoring
  • Gram-Positive Bacterial Infections / microbiology
  • Humans
  • Linezolid / pharmacology
  • Lipoglycopeptides / pharmacology
  • Microbial Sensitivity Tests
  • Oxazolidinones / pharmacology
  • Taiwan / epidemiology
  • Tetracyclines / pharmacology
  • Tetrazoles / pharmacology
  • Tigecycline / pharmacology
  • Vancomycin / pharmacology
  • Vancomycin-Resistant Enterococci / drug effects*
  • Virginiamycin / pharmacology

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Lipoglycopeptides
  • Oxazolidinones
  • Tetracyclines
  • Tetrazoles
  • eravacycline
  • omadacycline
  • Virginiamycin
  • quinupristin-dalfopristin
  • Vancomycin
  • Tigecycline
  • tedizolid
  • Linezolid
  • Daptomycin
  • telavancin